Research & Education

Publications

Select Articles Published by the Committee and Committee Members:
  • Tsao MS, Kerr KM, Kockx M, et al. PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of Blueprint phase 2 project. J Thorac Oncol. 2018;13(9):1302-1311.
  • Nicholson AG, Torkko K, Viola P et al. Interobserver Variation among Pathologists and Refinement of Criteria in Distiguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung. J Thorac Oncol. 2018;13(2):205-217.
  • Thunnissen E, Witte BI, Noguchi M, Yatabe Y. Reply to Letter "The Use of Immunohistochemistry Improves the Diagnosis of Small Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases." J Thorac Oncol. 2017;12(6):e70-e71.
  • Thunnissen E, Borczuk AC, Flieder DB, et al. The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases. J Thorac Oncol. 2017;12(2):334-346.
  • Hirsch F, McElhinny A, Stanforth D, et al. PD-L1 Immunochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. J Thorac Oncol. 2017;12(2):208-222.
  • Galateau-Salle, F, Churg A, Travis WD, et al. The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification. J Thorac Oncol. 2016;11(2):142-54.
  • Travis WD, Brambilla E, Burke AP, et al. Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. J Thorac Oncol. 2015;10(9):1240-1242.
  • Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol. 2015;10(9):1243-1260.
  • Wynes MW, Sholl LM, Dietel M, et al. An International Interpretation Study Using the ALK IHC Antibody D5F3 and a Sensitive Detection Kit Demonstrates High Concordance between ALK IHC and ALK FISH and ALK FISH between evaluators. J Thorac Oncol. 2014;9(5):631-638
  • Travis WD, Brambilla E, Noguchi M, et al. Diagnosis of Lung Adenocarcinoma in Resected Specimens: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/ European Respiratory Society Classification. Arch Pathol Lab Med. 2013;137(5):685–705
  • Travis WD, Brambilla E, Noguchi M, et al. Diagnosis of Lung Cancer in Small Biopsies and Cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/ European Respiratory Society Classification. Arch Pathol Lab Med. 2013;137(5):668–684
  • Austin JH, Garg K, Aberle D, et al. Radiologic Implications of the 2011 Classification of Adenocarcinoma of the Lung. Radiology. 2013;266(1):62–71.
  • Lindeman NI, Cagle PT, Beasley MB, et al. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol. 2013;8(7):823–859.
  • Thunnissen E, Beasley MB, Borczuk AC, et al. Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study. Mod Pathol. 2012;25:1574–1583.
  • Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: International Multidisciplinary Classification of Lung Adenocarcinoma: Executive Summary. Proc Am Thorac Soc. 2011;8(5):381–385.
  • Travis WD, Brambilla E, Van Schil P, et al. Paradigm shifts in lung cancer as defined in the new IASLC/ATS/ERS lung adenocarcinoma classification. Eur Respir J. 2011;38:239–243.
     
  • Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol. 2011;6(2):244–285.
     
  • Kwak EL1, Bang YJ, Camidge DR, et al. Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer. N Engl J Med. 2010;363(18):1693–1703.
     
  • Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical Features and Outcome of Patients With Non-Small-Cell Lung Cancer Who Harbor EML4-ALK. J Clin Oncol. 2009;27(26):4247–4253.
     
  • Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561–566.
     
  • Lim E, Goldstraw P, Nicholson AG, et al. Proceedings of the IASLC International Workshop on Advances in Pulmonary Neuroendocrine Tumors 2007. J Thorac Oncol. 2008;3(10):1194–1201.
     
  • Travis WD, Garg K, Franklin WA, et al. Bronchioloalveolar Carcinoma and Lung Adenocarcinoma: The Clinical Importance and Research Relevance of the 2004 World Health Organization Pathologic Criteria. J Thorac Oncol. 2006;1(9 Supp1):S13–S19.
     
  • Miller VA, Hirsch FR, Johnson DH. Systemic Therapy of Advanced Bronchioloalveolar Cell Carcinoma: Challenges and Opportunities. J Clin Oncol. 2005;23(14):3288–3293.
     
  • Travis WD, Garg K, Franklin WA, et al. Evolving Concepts in the Pathology and Computed Tomography Imaging of Lung Adenocarcinoma and Bronchioloalveolar Carcinoma. J Clin Oncol. 2005;23(14):3279–3287.
     
  • Burke L, Flieder DB, Guinee DG, et al. Prognostic Implications of Molecular and Immunohistochemical Profiles of the Rb and p53 Cell Cycle Regulatory Pathways in Primary Non-Small Cell Lung Carcinoma. Clin Cancer Res. 2005;11(1):232–241.
     
  • Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2004;22(6):1103–1109.
  • He P, Varticovski L, Bowman ED, et al. Identification of carboxypeptidase E and γ-glutamyl hydrolase as biomarkers for pulmonary neuroendocrine tumors by cDNA microarray. Hum Pathol. 2004;35(10):1196–1209.
  • Bepler G, Neumann K, Holle R, Havemann K, Kalbfleisch H. Clinical relevance of histologic subtyping in small cell lung cancer. Cancer. 1989;64(1):74–79.
  • Guinee DG Jr, Travis WD, Trivers GE, et al. Gender comparisons in human lung cancer: analysis of p53 mutations, anti-p53 serum antibodies and C-erbB-2 expression. Carcinogenesis. 1995;16(5):993–1002.
  • Moro D, Brichon PY, Brambilla E, Veale D, Labat F, Brambilla C. Basaloid bronchial carcinoma. A histologic group with a poor prognosis. Cancer. 1994;73(11):2734–2739.
  • Brambilla E, Moro D, Veale D, et al. Basal cell (basaloid) carcinoma of the lung: A new morphologic and phenotypic entity with separate prognostic significance. Hum Pathol. 1992;23(9):993–1003.
  • Hirsch FR, Matthews MJ, Aisner S, et al. Histopathologic classification of small cell lung cancer. Changing concepts and terminology. Cancer. 1988;62(5):973–977.
  • Roggli VL, Vollmer RT, Greenberg SD, McGavran MH, Spjut HJ, Yesner R. Lung cancer heterogeneity: A blinded and randomized study of 100 consecutive cases. Hum Pathol. 1985;16(6):569–579.
  • Gazdar AF, Carney DN, Nau MM, Minna JD. Characterization of Variant Subclasses of Cell Lines Derived from Small Cell Lung Cancer Having Distinctive Biochemical, Morphological, and Growth Properties. Cancer Res. 1985;45(6):2924–2930.
  • Radice PA, Matthews MJ, Ihde DC, et al. The clinical behavior of “mixed” small cell/large cell bronchogenic carcinoma compared to “pure” small cell subtypes. Cancer. 1982;50(12):2894–2902.
  • Auerbach O, Hammond EC, Garfinkel L. Changes in Bronchial Epithelium in Relation to Cigarette Smoking, 1955–1960 vs. 1970–1977. N Engl J Med. 1979;300:381–386.
  • Oswald NC, Hinson KF, Canti G, Miller AB. The diagnosis of primary lung cancer with special reference to sputum cytology. Thorax. 1971;26(6):623–627.